Tumor suppressor p53 and its gain-of-function mutants in cancer

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 3, 2014, Pages 170-179

  Liu, Juan ^a   Zhang, Cen ^a   Feng, Zhaohui ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

gain of function; mutant p53; p53; tumor suppressor; tumor therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER THERAPY; CELL CYCLE CHECKPOINT; DRUG EFFECT; ENERGY METABOLISM; GAIN-OF-FUNCTION; GENETICS; HUMAN; MUTANT P53; MUTATION; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR;

GAIN-OF-FUNCTION; MUTANT P53; P53; TUMOR SUPPRESSOR; TUMOR THERAPY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; ENERGY METABOLISM; HUMANS; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84897731197     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt144     Document Type: Review

References (112)

1. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature 2000, 408: 307-310.
2. Feng Z and Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010, 20: 427-434.
3. Vousden KH and Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137: 413-431.
4. Hollstein M, Sidransky D, Vogelstein B and Harris CC. p53 mutations in human cancers. Science 1991, 253: 49-53.
5. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P and Harris CC. TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004, 157: 247-270.
6. Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A and Zehbe I. The role of TP53 in Cervical carcinogenesis. Hum Mutat 2003, 21: 307-312.
7. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63: 1129-1136.
8. Wade M, Li YC and Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013, 13: 83-96.
9. Strong LC. General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome. Gynecol Oncol 2003, 88: S4-S7; discussion S11-13.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr, Butel JS and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356: 215-221.
11. Muller PA and Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013, 15: 2-8.
12. Freed-Pastor WA and Prives C. Mutant p53: one name, many proteins. Genes Dev 2012, 26: 1268-1286.
13. Harris SL and Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24: 2899-2908.
14. Brooks CL and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006, 21: 307-315.
15. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1: 45-49.
16. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993, 362: 849-852.
17. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362: 847-849.
18. Riley T, Sontag E, Chen P and Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9: 402-412.
19. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J and MacLean KH, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003, 4: 321-328.
20. Green DR and Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458: 1127-1130.
21. Vaseva AV and Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta 2009, 1787: 414-420.
22. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377: 552-557.
23. Deng C, Zhang P, Harper JW, Elledge SJ and Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82: 675-684.
24. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S and Kinzler KW, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997, 1: 3-11.
25. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV and Plunkett BS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-Telangiectasia. Cell 1992, 71: 587-597.
26. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V and Cordon-Cardo C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445: 656-660.
27. Kortlever RM, Higgins PJ and Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006, 8: 877-884.
28. Levine AJ and Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9: 749-758.
29. Vousden KH and Ryan KM. p53 and metabolism. Nat Rev Cancer 2009, 9: 691-700.
30. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144: 646-674.
31. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O and Hurley PJ, et al. p53 regulates mitochondrial respiration. Science 2006, 312: 1650-1653.
32. Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M and Rotter V. Regulation of AIF expression by p53. Cell Death Differ 2006, 13: 2140-2149.
33. Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S and Chretien D, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 2007, 39: 776-780.
34. Hu W, Zhang C, Wu R, Sun Y, Levine A and Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010, 107: 7455-7460.
35. Schwartzenberg-Bar-Yoseph F, Armoni M and Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004, 64: 2627-2633.
36. Kawauchi K, Araki K, Tobiume K and Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008, 10: 611-618.
37. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R and Gottlieb E, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126: 107-120.
38. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ and Hu W, et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and theWarburg effect. Proc Natl Acad Sci USA 2011, 108: 16259-16264.
39. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M and Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011, 13: 310-316.
40. Budanov AV, Sablina AA, Feinstein E, Koonin EV and Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004, 304: 596-600.
41. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11: 1306-1313.
42. Liang Y, Liu J and Feng Z. The regulation of cellular metabolism by tumor suppressor p53. Cell Biosci 2013, 3: 9.
43. Bensaad K and Vousden KH. p53: new roles in metabolism. Trends Cell Biol 2007, 17: 286-291.
44. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev 2011, 25: 1999-2010.
45. Feng Z, Zhang H, Levine AJ and Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005, 102: 8204-8209.
46. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR and Gasco M, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126: 121-134.
47. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA and Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010, 22: 181-185.
48. Zhao YG, Zhao H, Miao L, Wang L, Sun F and Zhang H. The p53-induced gene Ei24 is an essential component of the basal autophagy pathway. J Biol Chem 2012, 287: 42053-42063.
49. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M and Criollo A, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008, 10: 676-687.
50. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A and Vicencio JM, et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008, 7: 3056-3061.
51. Feng Z, Zhang C, Wu R and Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011, 3: 44-50.
52. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012, 12: 613-626.
53. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH and Feldmann G, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26: 745-752.
54. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447: 1130-1134. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y and Xue W, et al.
55. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N and Bentwich Z, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26: 731-743.
56. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S and Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460: 529-533.
57. Leveille N, Elkon R, Davalos V, Manoharan V, Hollingworth D, Oude Vrielink J and le Sage C, et al. Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nat Commun 2011, 2: 513.
58. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM and Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002, 1: 289-298.
59. Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ and Lowe SW. Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci USA 2004, 101: 9333-9338.
60. Michalak EM, Villunger A, Adams JM and Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 2008, 15: 1019-1029.
61. Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS and Chang S. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 2007, 8: 497-503.
62. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK and Multani A, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004, 36: 63-68.
63. Van Nguyen T, Puebla-Osorio N, Pang H, Dujka ME and Zhu C. DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: A mouse model. J Exp Med 2007, 204: 1453-1461.
64. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM and Kenzelmann Broz D, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145: 571-583.
65. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y and Baer R, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149: 1269-1283.
66. Tanaka T, Ohkubo S, Tatsuno I and Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 2007, 130: 638-650.
67. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S and Campargue I, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001, 8: 781-794.
68. Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA and Lee SW. Hzf determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 2007, 130: 624-637.
69. Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM and Look AT. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005, 123: 641-653.
70. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D and Khalil AM, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010, 142: 409-419.
71. Harris CC and Hollstein M. Clinical implications of the p53 tumorsuppressor gene. N Eng J Med 1993, 329: 1318-1327.
72. Wolf D, Harris N and Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-Transformed cell line by transfection of a functional p53 gene. Cell 1984, 38: 119-126.
73. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M and Finlay C, et al. Gain of function mutations in p53. Nat Genet 1993, 4: 42-46.
74. Brosh R and Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009, 9: 701-713.
75. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X and Lin M, et al. Tumor-Associated mutant p53 drives the Warburg effect. Nat Commun 2013, 4: 2935.
76. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM and Valentin-Vega YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119: 861-872.
77. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT and Crowley D, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119: 847-860.
78. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY and Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000, 113 (Pt 10): 1661-1670.
79. Li Y and Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007, 26: 2220-2225.
80. Gaiddon C, Lokshin M, Ahn J, Zhang T and Prives C. A subset of tumorderived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001, 21: 1874-1887.
81. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A and Blandino G, et al. Gain of function of mutant p53: the mutant p53/ NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006, 10: 191-202.
82. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z and Shiff I, et al. Modulation of the vitamin D3 response by cancer-Associated mutant p53. Cancer Cell 2010, 17: 273-285.
83. Chicas A, Molina P and Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun 2000, 279: 383-390.
84. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R and Barsotti A, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148: 244-258.
85. Song H, HollsteinM and Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007, 9: 573-580.
86. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A and Blandino G, et al. Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res 2009, 69: 4818-4826.
87. Restle A, Farber M, Baumann C, Bohringer M, Scheidtmann KH, Muller-Tidow C andWiesmuller L. Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. Nucleic Acids Res 2008, 36: 5362-5375.
88. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E and Capaci V, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011, 20: 79-91.
89. Muller BF, Paulsen D and Deppert W. Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene 1996, 12: 1941-1952.
90. Will K, Warnecke G, Wiesmuller L and Deppert W. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. Proc Natl Acad Sci USA 1998, 95: 13681-13686.
91. Gohler T, Jager S, Warnecke G, Yasuda H, Kim E and Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 2005, 33: 1087-1100.
92. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H and Sudo S, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32: 3286-3295.
93. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB and Lim SP, et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2013, 32: 2992-3000.
94. Wang W, Cheng B, Miao L, Mei Y and Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis 2013, 4: e574.
95. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F and Muti P, et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012, 19: 1038-1048.
96. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL and Leung ML, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010, 467: 986-990.
97. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L and Newman J, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445: 661-665.
98. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T and Quintas-Cardama A, et al. Restoring expression of wild-Type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011, 121: 893-904.
99. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ and Hong WK, et al. Retrovirus-mediated wild-Type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996, 2: 985-991.
100. Tazawa H, Kagawa S and Fujiwara T. Advances in adenovirus-mediated p53 cancer gene therapy. Expert Opin Biol Ther 2013, 13: 1569-1583.
101. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z and Kong N, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303: 844-848.
102. Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S and Yang D, et al. MI-219-zinc combination: A new paradigm in MDM2 inhibitorbased therapy. Oncogene 2011, 30: 117-126.
103. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M and Pramanik A, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10: 1321-1328.
104. Wang W, Takimoto R, Rastinejad F and El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003, 23: 2171-2181.
105. Johnson WD, Muzzio M, Detrisac CJ, Kapetanovic IM, Kopelovich L and McCormick DL. Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs. Toxicology 2011, 289: 141-150.
106. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F and Moll UM. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 2011, 9: 577-588.
107. Li D, Marchenko ND and Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011, 18: 1904-1913.
108. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E and Frolova EI, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008, 105: 6302-6307.
109. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P and Bergman J, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. NatMed 2002, 8: 282-288.
110. Farnebo M, Bykov VJ and Wiman KG. The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010, 396: 85-89.
111. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR and Athar M. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 2007, 117: 3753-3764.
112. Yu X, Vazquez A, Levine AJ and Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell 2012, 21: 614-625.